In contrast, a recent study analyzed two KP modulation strategies: inhibition of IDO-1 with 1-methyl-tryptophan and inhibition of KMO in chronic stage EAE (aiming to model the progressive forms of MS). The gene discussed is NPPA; the disease is myeloid sarcoma.